A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease
Tekijät: Salihovic, Samira; Nyström, Niklas; Mathisen, Charlotte Bache-Wiig; Kruse, Robert; Olbjørn, Christine; Andersen, Svend; Noble, Alexandra J.; Dorn-Rasmussen, Maria; Bazov, Igor; Perminow, Gøri; Opheim, Randi; Detlie, Trond Espen; Huppertz-Hauss, Gert; Hedin, Charlotte R. H.; Carlson, Marie; Öhman, Lena; Magnusson, Maria K.; Keita, Åsa V.; Söderholm, Johan D.; D’Amato, Mauro; Orešič, Matej; Wewer, Vibeke; Satsangi, Jack; Lindqvist, Carl Mårten; Burisch, Johan; Uhlig, Holm H.; Repsilber, Dirk; Hyötyläinen, Tuulia; Høivik, Marte Lie; Halfvarson, Jonas
Kustantaja: Springer Nature
Julkaisuvuosi: 2024
Journal: Nature Communications
Tietokannassa oleva lehden nimi: Nature communications
Lehden akronyymi: Nat Commun
Artikkelin numero: 4567
Vuosikerta: 15
Numero: 1
eISSN: 2041-1723
DOI: https://doi.org/10.1038/s41467-024-48763-7
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/454780843
Improved biomarkers are needed for pediatric inflammatory bowel disease. Here we identify a diagnostic lipidomic signature for pediatric inflammatory bowel disease by analyzing blood samples from a discovery cohort of incident treatment-naïve pediatric patients and validating findings in an independent inception cohort. The lipidomic signature comprising of only lactosyl ceramide (d18:1/16:0) and phosphatidylcholine (18:0p/22:6) improves the diagnostic prediction compared with high-sensitivity C-reactive protein. Adding high-sensitivity C-reactive protein to the signature does not improve its performance. In patients providing a stool sample, the diagnostic performance of the lipidomic signature and fecal calprotectin, a marker of gastrointestinal inflammation, does not substantially differ. Upon investigation in a third pediatric cohort, the findings of increased lactosyl ceramide (d18:1/16:0) and decreased phosphatidylcholine (18:0p/22:6) absolute concentrations are confirmed. Translation of the lipidomic signature into a scalable diagnostic blood test for pediatric inflammatory bowel disease has the potential to support clinical decision making.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
Open access funding provided by Örebro University.
